BioStem Technologies, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioStem Technologies, Inc.
With valuations down and borrowing costs up, many industry insiders are expecting Darwinian scenes in biotech this year. Survival of the fittest is the order of the day: companies with riskier, less commercially defined propositions will struggle, while platform companies with multiple shots on strong goals will increasingly find favor in a more risk-averse environment.
A planned Phase II trial for PLK1 inhibitor onvansertib in KRAS-mutant colorectal cancer may support accelerated approval, but results are two years off and the company cut its prostate cancer plans to conserve cash.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
Brand litigants are beginning to argue that post-Markman application tweaks are in essence new applications eligible for new 30-month stays.
- Other Names / Subsidiaries
- BioStem Life Sciences, Inc
- Caribbean International Holdings, Inc
- Grupo Impulso De Incentivacion Para Nuevas Tecnologías (GIINT)
- Nesvik Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.